Quantcast

Latest acute leukemia Stories

2014-06-27 12:26:33

Study published in Clinical Cancer Research and co-led by Adaptive Biotechnologies and the University of Washington demonstrates clinical utility of Next Generation Immune Profiling SEATTLE, June 27, 2014 /PRNewswire/ -- Adaptive Biotechnologies today announced results demonstrating enhanced accuracy and sensitivity of clonoSEQ in identifying risk of relapse in patients with B-cell Acute Lymphoblastic Leukemia (B-ALL), a childhood leukemia, compared to flow cytometry, the current...

2014-06-12 04:22:18

SEATTLE, June 12, 2014 /PRNewswire/ -- CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) today announced the initiation of an international cooperative group Phase 2 clinical trial of tosedostat in combination with low-dose cytarabine in older patients with Acute Myeloid Leukemia (AML) or high risk Myelodysplastic Syndrome (MDS). Tosedostat is a first-in-class selective inhibitor of aminopeptidases, which are required by tumor cells to provide amino acids necessary for growth and tumor...

2014-06-10 08:31:13

Study Meets Pre-Specified CR/CRi Rate in First Nine Patients SAN DIEGO, June 10, 2014 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced preliminary response data from the first stage of a two-stage, open-label Phase II clinical study of its investigational drug candidate Pracinostat in combination with Vidaza(®) (azacitidine) in elderly patients with newly diagnosed acute myeloid...

2014-05-22 16:26:35

The Leukemia & Lymphoma Society and Oregon Health & Sciences University forged Beat AML collaboration to find effective therapies for acute myeloid leukemia patients WHITE PLAINS, N.Y., May 22, 2014 /PRNewswire-USNewswire/ -- The Leukemia & Lymphoma Society (LLS) today announced a $4 million commitment by the Harry T. Mangurian, Jr. Foundation to support a groundbreaking collaboration between LLS and with Brian Druker, M.D., of Oregon Health and Science University to "Beat...

2014-05-07 08:32:14

First-in-class DOT1L Inhibitor in Clinical Development as Potential Personalized Therapeutic for Patients with Genetically Defined Acute Leukemias CAMBRIDGE, Mass., May 7, 2014 /PRNewswire/ -- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced the initiation of a Phase 1b open-label clinical study of EPZ-5676 in pediatric patients with acute leukemias...

2014-04-25 09:23:29

CPX-351 treatment leads to higher chances of remission compared to standard options in AML Moffitt Cancer Center researchers say clinical trials for a new experimental drug to treat acute myeloid leukemia (AML) are very promising. Patients treated with CPX-351, a combination of the chemotherapeutic drugs cytarabine and daunorubicin, are showing better responses than patients treated with the standard drug formulation. "Acute myeloid leukemia is an aggressive blood cancer with very low...

2014-04-13 23:01:08

Transparency Market Research Report Added "Blood Disease Treatment Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019" to its database. Browse Full Report: http://www.transparencymarketresearch.com/blood-disease-treatment-drugs.html. Albany, New York, USA (PRWEB) April 13, 2014 Blood comprises of red blood cells, white blood cells, plasma and platelets. Sometimes, people might be affected with different types of blood disorders and...

2014-04-09 09:57:59

Research in mice and human cell lines has identified an experimental compound dubbed TTT-3002 as potentially one of the most potent drugs available to block genetic mutations in cancer cells blamed for some forms of treatment-resistant leukemia. Results of the research by Johns Hopkins Kimmel Cancer Center investigators, described March 6 in the journal Blood, show that two doses a day of TTT-3002 eliminated leukemia cells in a group of mice within 10 days. The treatment performed as well...

2014-04-08 08:30:19

SAN DIEGO, April 8, 2014 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the initiation of the QUANTUM-R Phase 3 clinical trial comparing quizartinib as monotherapy to chemotherapy regimens in relapsed/refractory acute myeloid leukemia (AML) patients with the FMS-like tyrosine kinase-3 (FLT3)-ITD mutation. "Initiation of...

2014-04-07 08:30:00

Phase I Demonstrates Quizartinib Tolerability in Combination with Chemotherapy SAN DIEGO, April 7, 2014 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the initiation of the Phase 2 cohort of the MD Anderson Cancer Center-sponsored Phase 1/2 study of quizartinib in combination with either 5-azacitidine or low dose...


Word of the Day
tessitura
  • The prevailing range of a vocal or instrumental part, within which most of the tones lie.
This word is Italian in origin and comes from the Latin 'textura,' web, structure.